Search research articles
Contact Us
Filters
Showing results (31-40 of 43) with videos related to
Page
of 5
Sort By:
Nature Communications
|
August 24, 2018
Half-metallic carbon nitride nanosheets with micro grid mode resonance structure for efficient photocatalytic hydrogen evolution
Gang Zhou, Yun Shan, Youyou Hu, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
December 15, 2021
Objective Response Predicts Survival in Advanced Hepatocellular Carcinoma Treated with Systemic Therapies
Masatoshi Kudo, Robert Montal, Richard S Finn, et al.
Liver Cancer
|
March 6, 2023
Hepatic Events and Viral Kinetics in Hepatocellular Carcinoma Patients Treated with Atezolizumab plus Bevacizumab
Chiun Hsu, Michel Ducreux, Andrew X Zhu, et al.
Journal for Immunotherapy of Cancer
|
November 30, 2022
Final results from TAIL: updated long-term efficacy of atezolizumab in a diverse population of patients with previously treated advanced non-small cell lung cancer
Andrea Ardizzoni, Sergio Azevedo, Belen Rubio-Viqueira, et al.
The Lancet. Oncology
|
July 17, 2023
Atezolizumab, vemurafenib, and cobimetinib in patients with melanoma with CNS metastases (TRICOTEL): a multicentre, open-label, single-arm, phase 2 study
Reinhard Dummer, Paola Queirolo, Pauline Gerard Duhard, et al.
The Lancet. Oncology
|
August 8, 2022
Atezolizumab, vemurafenib, and cobimetinib in patients with melanoma with CNS metastases (TRICOTEL): a multicentre, open-label, single-arm, phase 2 study
Reinhard Dummer, Paola Queirolo, Ana Maria Abajo Guijarro, et al.
Chinese Medical Journal
|
December 22, 2025
First-line atezolizumab monotherapy vs. single-agent chemotherapy in patients with advanced or metastatic non-small cell lung cancer who are ineligible for platinum-based therapy: Analysis of the IPSOS Asian subpopulation
Baohui Han, Solange Peters, Anh Tuan Le, et al.
International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society
|
June 10, 2024
A non-comparative, randomized, phase II trial of atezolizumab or atezolizumab plus tiragolumab for programmed death-ligand 1-positive recurrent cervical cancer (SKYSCRAPER-04)
Ritu Salani, Mary McCormack, Yong-Man Kim, et al.
International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society
|
April 14, 2025
A non-comparative, randomized, phase II trial of atezolizumab or atezolizumab plus tiragolumab for programmed death-ligand 1-positive recurrent cervical cancer (SKYSCRAPER-04)
Ritu Salani, Mary McCormack, Yong-Man Kim, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
February 13, 2019
A Phase I, Open-Label, Multicenter, Dose-escalation Study of the Oral Selective FGFR Inhibitor Debio 1347 in Patients with Advanced Solid Tumors Harboring <i>FGFR</i> Gene Alterations
Martin H Voss, Cinta Hierro, Rebecca S Heist, et al.
Page
of 5
Search research articles
Search
Showing results (31-40 of 43) with videos related to
Sort By:
Page
of 5
Nature Communications
|
August 24, 2018
Half-metallic carbon nitride nanosheets with micro grid mode resonance structure for efficient photocatalytic hydrogen evolution
Gang Zhou, Yun Shan, Youyou Hu, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
December 15, 2021
Objective Response Predicts Survival in Advanced Hepatocellular Carcinoma Treated with Systemic Therapies
Masatoshi Kudo, Robert Montal, Richard S Finn, et al.
Liver Cancer
|
March 6, 2023
Hepatic Events and Viral Kinetics in Hepatocellular Carcinoma Patients Treated with Atezolizumab plus Bevacizumab
Chiun Hsu, Michel Ducreux, Andrew X Zhu, et al.
Journal for Immunotherapy of Cancer
|
November 30, 2022
Final results from TAIL: updated long-term efficacy of atezolizumab in a diverse population of patients with previously treated advanced non-small cell lung cancer
Andrea Ardizzoni, Sergio Azevedo, Belen Rubio-Viqueira, et al.
The Lancet. Oncology
|
July 17, 2023
Atezolizumab, vemurafenib, and cobimetinib in patients with melanoma with CNS metastases (TRICOTEL): a multicentre, open-label, single-arm, phase 2 study
Reinhard Dummer, Paola Queirolo, Pauline Gerard Duhard, et al.
The Lancet. Oncology
|
August 8, 2022
Atezolizumab, vemurafenib, and cobimetinib in patients with melanoma with CNS metastases (TRICOTEL): a multicentre, open-label, single-arm, phase 2 study
Reinhard Dummer, Paola Queirolo, Ana Maria Abajo Guijarro, et al.
Chinese Medical Journal
|
December 22, 2025
First-line atezolizumab monotherapy vs. single-agent chemotherapy in patients with advanced or metastatic non-small cell lung cancer who are ineligible for platinum-based therapy: Analysis of the IPSOS Asian subpopulation
Baohui Han, Solange Peters, Anh Tuan Le, et al.
International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society
|
June 10, 2024
A non-comparative, randomized, phase II trial of atezolizumab or atezolizumab plus tiragolumab for programmed death-ligand 1-positive recurrent cervical cancer (SKYSCRAPER-04)
Ritu Salani, Mary McCormack, Yong-Man Kim, et al.
International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society
|
April 14, 2025
A non-comparative, randomized, phase II trial of atezolizumab or atezolizumab plus tiragolumab for programmed death-ligand 1-positive recurrent cervical cancer (SKYSCRAPER-04)
Ritu Salani, Mary McCormack, Yong-Man Kim, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
February 13, 2019
A Phase I, Open-Label, Multicenter, Dose-escalation Study of the Oral Selective FGFR Inhibitor Debio 1347 in Patients with Advanced Solid Tumors Harboring <i>FGFR</i> Gene Alterations
Martin H Voss, Cinta Hierro, Rebecca S Heist, et al.
Page
of 5